1,058
Views
29
CrossRef citations to date
0
Altmetric
Research Article

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis

, , , , , , , , , , , & show all
Pages 253-259 | Accepted 20 Dec 2012, Published online: 07 Mar 2013
 

Abstract

Objectives: The retention of the anti-rheumatic agent tocilizumab (TCZ) has not been well documented in patients with rheumatoid arthritis (RA). We conducted an observational study to compare the retention of TCZ and anti-tumour necrosis factor (TNF) drugs in the treatment of patients with RA.

Method: We reviewed continuation rates and causes of discontinuation of biological agents (biologics) by assessing medical records of patients with RA who were administered biologics at our institute from September 1999 to April 2012, using the Osaka University Biologics for Rheumatic Diseases (BiRD) registry.

Results: A total of 401 patients were included. TCZ, infliximab (IFX), etanercept (ETN), and adalimumab (ADA) were administered to 97, 103, 143, and 58 patients, respectively. There were some differences between the baseline characteristics of the groups. The median duration (range) of TCZ, IFX, ETN, and ADA administration was 2.5 (0.1–12.6), 1.9 (0.0–7.7), 2.9 (0.0–11.3), and 1.3 (0.0–3.4) years, respectively. Continuation rates for TCZ and ETN were significantly higher than those for IFX and ADA. Multivariate analyses showed that discontinuation due to lack or loss of efficacy was significantly less common in the TCZ group than in the other groups. Discontinuation due to overall adverse events was not significantly different between treatment groups.

Conclusion: TCZ and ETN show better retention than IFX or ADA in the treatment of RA.

Acknowledgements

We thank the following rheumatologists for their critical comments and suggestions and for responding to our inquiries: N Nishimoto, S Ohshima, J Hashimato, R Yasunami, H Ohwaki, K Takahi, K Saito, K Yamamoto, W Ito, M Kai, Y Ito, S Sakito, O Akahori, T Takashima, A Nampei, T Ikawa, S Hirohata, Y Kita, S Fujii, T Harada, H Ninomiya, M Yajima, and M Takei.

This work was supported by research grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (A.K.); grants-in-aid from the Ministry of Health, Labour and Welfare (A.K.); Funding Programme for Next-Generation World-Leading Researchers (NEXT Program) (A.K.); and Special Coordination Funds for Promoting Science and Technology (A.K.).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.